HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Blinatumomab: a novel agent to treat minimal residual disease in patients with acute lymphoblastic leukemia.

AuthorsAnjali S Advani
JournalClinical advances in hematology & oncology : H&O (Clin Adv Hematol Oncol) Vol. 9 Issue 10 Pg. 776-7 (Oct 2011) ISSN: 1543-0790 [Print] United States
PMID22252580 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Bispecific
  • Antigens, CD19
  • Antineoplastic Agents
  • CD3 Complex
  • blinatumomab
Topics
  • Antibodies, Bispecific (administration & dosage, immunology, therapeutic use)
  • Antigens, CD19 (immunology)
  • Antineoplastic Agents (administration & dosage, immunology, therapeutic use)
  • Apoptosis
  • CD3 Complex (immunology)
  • Clinical Trials as Topic
  • Disease-Free Survival
  • Flow Cytometry
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Immunophenotyping
  • Lymphocyte Activation
  • Neoplasm, Residual (drug therapy, immunology, mortality)
  • Polymerase Chain Reaction
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy, immunology, mortality)
  • Secondary Prevention
  • T-Lymphocytes (drug effects, enzymology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: